OptiNose

OptiNose — Investor Presentation (December 2018)

15 slides from OptiNose's investor presentation, Dec 12, 2018

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Exhibit 99.1 Building a Leading ENT / Allergy Specialty Company Corporate Presentation December 12, 2018

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu

  3. Slide 3: Emerging Growth Company with Approved Products

    Emerging Growth Company with Approved Products BUILDING A LEADING ENT / ALLERGY SPECIALTY COMPANY XHANCE® presents a significant opportunity in the ENT/Allergy market with the current indication XHANCE offers “pipeline within a product” opportunities Additional business development expected to focus

  4. Slide 4: Optinose EDS Technology is a Platform for Development

    Optinose EDS Technology is a Platform for Development Note: The Avanir License Agreement is expected to terminate on March 10, 2019. Optinose is evaluating options including seeking a new 4 license partner.

  5. Slide 5: Chronic Rhinosinusitis is an Attractive Market for XHANCE with High Unmet Need

    Chronic Rhinosinusitis (CRS) is an Attractive Market for XHANCE…with High Unmet Need High Burden 30 Million US Adults suffer from CRS • Disease persists for many years and up to 10 million • Significant quality of life impact of them have nasal (comparable to CHF, COPD, Angina) polyps (NP) 9.75 Mill

  6. Slide 6: Optinose EDS Can Deliver Drug High & Deep in the Nose

    Optinose EDS Can Deliver Drug High & Deep in the Nose KEY TO TREATING CRS (W OR W/OUT POLYPS) Optinose EDS w/Exhalation Sinus drainage regions are key treatment targets Nasal Spray w/o Exhalation Intranasal steroids are TOPICALLY ACTING medications: Delivery to sites of chronic inflammation and nasa

  7. Slide 7: Optinose Key Priorities

    Optinose Key Priorities Accelerate XHANCE® prescription growth | follow-on indication for the treatment of chronic Advance our clinical program for XHANCE for a sinusitis Support our commercial and development objectives through efficient use of capital = $220 Million of cash as of September 30, 201

  8. Slide 8: XHANCE Launch Update

    XHANCE Launch Update optinose

  9. Slide 9: Encouraging Feedback From Xperience Patient Survey

    Encouraging Feedback From Xperience Patient Survey Patient responses prior to Month 2 refill from March - August 2018 Total Prior User of Prior User Respondents Flonase / Nasonex Budesonide Rinse (N=2,733) (n=820) (N=175) Patient Satisfaction 89% 90% 90% Experience Symptom Improvement 80% 79% 68% Pr

  10. Slide 10: Examples of Positive XHANCE Physician Feedback

    Examples of Positive XHANCE Physician Feedback* “The polyps were significantly reduced and patient symptoms improved. The results were dramatic.” - ENT *Testimonials and images reflect real life experience of those who have reported using XHANCE. However, they are individual results and results do v

  11. Slide 11: Our Updated Patient Assistance Program Addresses Affordability and Access

    Our Updated Patient Assistance Program Addresses Physician Perceptions Regarding Affordability and Access XTENDED Patient Support . $0 co-pay for initial Rx for all commercial patients . Maximum out of pocket of $30 for refills for covered commercial patients . Maximum out of pocket of $50 for non-c

  12. Slide 12: Additional Commercial Updates

    Additional Commercial Updates Market Access . Nationally, we believe more than 75% of commercial lives are in a plan where XHANCE is covered in a Tier 3 formulary position* . Recently signed first Part D contract and expanding Medicaid coverage Writers . More than 3,800 physicians have written a pre

  13. Slide 13: XHANCE Monthly Prescription Volumes

    XHANCE Monthly Prescription Volumes New promotional materials and patient affordability program rolled out week of August 17 +42% XHANCE 5,000 4,880 4,000 3,450 3,440 3,360 3,191 3,081 3,000 2,225 2,000 1,000 806 0 Mar Apr May Jun Jul Aug Sep Oct Market TRx for Intranasal Steroids increased 10% from

  14. Slide 14: XHANCE Weekly Prescription Volumes

    XHANCE Weekly Prescription Volumes New promotional materials and patient affordability program rolled out week of August 17 1800 +18% +25% 4,900 +10% 1380 4,157 1322 3,327 1236 1200 1117 1124 3,030 1075 1004 962 910 893 811 830 841 749 712 714 698 639 664 611 600 600 0 Jul 06 Jul 13 Jul 20 Jul 27 Au

  15. Slide 15: Investor Relations

    Investor Relations – NASDAQ: OPTN At 30 September 2018: Analyst Coverage1 – ~$220 million in cash – Long-term debt: $75 million BMO: Gary Nachman – 41.2 million common shares o/s – 8.0 million options & warrants o/s Jefferies: David Steinberg Cantor Fitzgerald: Brandon Folkes Optinose Investor Conta

OptiNose — Investor Presentation (December 2018) on 6ix